Daiichi Sankyo has reported that the Phase I/II/III clinical trial of a messenger ribonucleic acid (mRNA) vaccine for Covid-19, DS-5670, as a booster met the primary endpoint.

The trial analysed the safety and efficacy of the booster dose of DS-5670.

It enrolled nearly 5,000 healthy adult and elderly participants in Japan.

These subjects had received the initial two-dose vaccine regimen with mRNA vaccines approved in the country a minimum of six months prior to enrolment.

The company commenced the trial in January this year to assess DS-5670 as a booster, with mRNA vaccines approved in the country as the control.

Geometric mean fold rise (GMFR) of neutralising antibody titer against the original SARS-CoV-2 viral strain in blood four weeks following dosing was the trial’s primary endpoint.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Learn more about Strategic Intelligence

According to the findings, the DS-5670 booster vaccine showed non-inferiority to the other mRNA vaccines approved in the country.

No safety concerns linked to the vaccine were reported in the trial.

Based on this data, the company will advance to prepare a new drug application for the vaccine in January next year.

Daiichi Sankyo also intends to carry out trials of bivalent vaccines against the original and Omicron viral strains.

The DS-5670 vaccine has been designed to produce antibodies against the receptor binding domain (RBD) of the virus’ spike protein.

In June this year, the company reported positive findings from a Phase III trial, where its quizartinib plus standard induction and consolidation chemotherapy demonstrated to offer a statistically significant and clinically meaningful improvement in overall survival in adults with FLT3-ITD positive acute myeloid leukaemia.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Optimise your cell therapy process: a guide to cell thawing

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.

Thank you.

You will receive an email shortly. Please check your inbox to download the Whitepaper.

By Cytiva Thematic

You have a right to withdraw your consent at any time, by clicking here. We may still continue to send you service-related and other non-promotional communications. For more information relating to our privacy practices, we invite you to review our privacy policy.